Abstract
Background and purpose
This study aimed to develop and validate a scoring system to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases from less radiosensitive tumors.
Patients and methods
The study included data from 176 patients with brain metastasis from renal cell carcinoma, malignant melanoma or colorectal cancer. Patients were divided into a test group (N = 88) and a validation group (N = 88). In the multivariate analysis of the test group, age, Karnofsky Performance Status and extracranial metastasis were significantly associated with survival. These three factors were included in the scoring system. The score for each factor was determined by dividing the 6-month survival rate (in %) by 10. The total score represented the sum of the three scores. According to the total scores—which ranged from 5 to14 points—three prognostic groups were created.
Results
The 6-month survival rates in the test group were 11 % for 5–8 points (N = 47, group A), 38 % for 9–11 points (N = 29, group B) and 83 % for 12–14 points (N = 12, group C). In the validation group the 6-month survival rates were 12, 31 and 75 %, respectively. Comparisons between the prognostic groups A, B and C of the test group with those of the validation group did not reveal any significant differences.
Conclusion
The new scoring system based on three independent prognostic factors can help to estimate the survival of patients with brain metastases from a less radiosensitive tumor. The score appears to be valid and reproducible.
Zusammenfassung
Hintergrund und Ziel
Ziel dieser Studie war es, einen Score zu entwickeln und zu validieren, mit dem die Überlebensprognose von Patienten mit Hirnmetastasen von gering strahlensensiblen Tumoren nach alleiniger Ganzhirnbestrahlung (WBRT) abgeschätzt werden kann.
Patienten und Methoden
Die Studie enthielt Daten von 176 Patienten mit Hirnmetastasen eines Nierenzellkarzinoms, eines malignen Melanoms oder eines kolorektalen Karzinoms, die in eine Testgruppe (n = 88) und eine Validierungsgruppe (n = 88) aufgeteilt wurden. In der Multivarianzanalyse der Testgruppe waren Alter, Karnofsky-Index und extrakranielle Metastasierung signifikant mit dem Überleben assoziiert. Diese 3 Faktoren wurden in dem Scoringsystem berücksichtigt. Der Score wurde für jeden Faktor ermittelt, indem die Überlebensrate nach 6 Monaten (in %) durch 10 dividiert wurde. Der jeweilige Gesamtscore entsprach der Summe der 3 Einzelscores. Unter Berücksichtigung der Gesamtscores, die zwischen 5 und 14 Punkten betrugen, wurden 3 Prognosegruppen gebildet.
Ergebnisse
Die Überlebensraten nach 6 Monaten in der Testgruppe betrugen 11 % bei 5–8 Punkten (n = 47, Gruppe A), 38 % bei 9–11 Punkten (n = 29, Gruppe B) und 83 % bei 12–14 Punkten (n = 12, Gruppe C). In der Validierungsgruppe lagen die Überlebensraten bei 12, 31 und 75 %. Die Vergleiche zwischen der Test- und der Validierungsgruppe für die 3 Prognosegruppen A, B und C ergaben keine signifikanten Unterschiede.
Schlussfolgerungen
Dieses neue Scoringsystem, das auf 3 unabhängigen Prognosefaktoren beruht, kann dazu beitragen, die Überlebensprognose von Patienten mit Hirnmetastasen von gering strahlensensiblen Tumoren abzuschätzen. Der Score erscheint valide und reproduzierbar.
References
Culine S, Bekradda M, Kramar A et al (1998) Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 83:2548–2553
DeAngelis LM, Delattre JY, Posner JB (1989) Radiation-induced dementia in patients cured of brain metastases. Neurology 39:789–796
Gaspar L, Scott C, Rotman M et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751
Heisterkamp C, Haatanen T, Schild SE, Rades D (2010) Dose escalation in patients receiving whole-brain radiotherapy for brain metastases from colorectal cancer. Strahlenther Onkol 186:70–75
Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Khuntia D, Brown P, Li J et al (2006) Whole-Brain radiotherapy in the management of brain metastases. J Clin Oncol 24:1295–1304
Kruser TJ, Chao ST, Elson P et al (2008) Multidisciplinary management of colorectal brain metastases. A retrospective study. Cancer 113:158–165
Marko NF, Weil RJ (2010) Radiotherapy. Neurocognitive considerations in the treatment of brain metastases. Nat Rev Clin Oncol 7:185–186
Meyners T, Heisterkamp C, Kueter JD et al (2010) Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis. BMC Cancer 10:582
Nieder C, Andratschke NH, Geinitz H et al (2012) Use of the Graded Prognostic Assessment (GPA) score in patients with brain metastases from primary tumours not represented in the diagnosis-specific GPA studies. Strahlenther Onkol 188:692–695
Rades D, Bohlen G, Dunst J et al (2008) Comparison of short-course versus long-course whole-brain radiotherapy in the treatment of brain metastases. Strahlenther Onkol 184:30–35
Rades D, Evers JN, Veninga T et al (2011) Shorter-course whole-brain radiotherapy for brain metastases in elderly patients. Int J Radiat Oncol Biol Phys 81:e469–e473
Rades D, Heisterkamp C, Huttenlocher S et al (2010) Dose escalation of whole-brain radiotherapy for brain metastases from melanoma. Int J Radiat Oncol Biol Phys 77:537–541
Rades D, Heisterkamp C, Schild SE (2010) Do patients receiving whole-brain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose? Int J Radiat Oncol Biol Phys 78:398–403
Rades D, Küter JD, Gliemroth J et al (2012) Resection plus whole-brain irradiation versus resection plus whole-brain irradiation plus boost for the treatment of single brain metastasis. Strahlenther Onkol 188:143–147
Rades D, Panzner A, Dziggel L et al (2012) Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer 118:3852–3859
Ruge MI, Kocher M, Maarouf M et al ( 2011) Comparison of stereotactic brachytherapy (125 iodine seeds) with stereotactic radiosurgery (LINAC) for the treatment of singular cerebral metastases. Strahlenther Onkol 187:7–14
Sperduto PW, Chao ST, Sneed PK et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77:655–661
Tan WS, Ho KS, Eu KW (2009) Brain metastases in colorectal cancers. World J Surg 33:817–821
Tsao MN, Lloyd N, Wong RK et al (2012) Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 18:4(CD003869)
Conflict of interest
On behalf of all authors, the corresponding author states that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dziggel, L., Segedin, B., Podvrsnik, N. et al. A survival score for patients with brain metastases from less radiosensitive tumors treated with whole-brain radiotherapy alone. Strahlenther Onkol 190, 54–58 (2014). https://doi.org/10.1007/s00066-013-0394-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-013-0394-2